Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex

Anti-Cancer Drugs

Volumn 15, Issue 3, 2004, Pages 255-263

  Yang, David J ^a   Bryant, Jerry ^a   Chang, Joe Y ^a   Mendez, Richard ^a   Oh, Chang Sok ^a   Yu, Dong Fang ^a   Ito, Megumi ^a   Azhdarinia, Ali ^a   Kohanim, Sahar ^a   Kim, E Edmund ^a   Lin, Edward ^a   Podoloff, Donald A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

99mTc EC celebrex; COX 2 imaging

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; TECHNETIUM 99M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG UPTAKE; ENZYME ACTIVITY; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RADIONUCLIDE IMAGING; RATS; RATS, INBRED F344; SULFONAMIDES; TECHNETIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 12144291289     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200403000-00010     Document Type: Article

References (30)

1. Bauer AK, Dwyer-Nield LD, Malkinson AM. High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis. 2000; 21:543-550.
2. Maihofner C, Probst-Cousin S, Bergmann M, Neuhuber W, Neundorfer B, Heuss D. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003; 18: 1527-1534.
3. Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 2000; 355:646-648.
4. Botting R. COX-1 and COX-3 inhibitors. Thromb Res 2003; 110:269-272.
5. Simmons DL. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 2003; 110:265-268.
6. Kawamori T, Wakabayashi K. COX-2 and prostanoid receptors: good targets for chemoprevention. J Environ Pathol Toxicol Oncol 2002; 21:149-153.
7. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000; 7:1377-1381.
8. 2 core. Inorg Chem 1981; 20:1629-1632.
9. Verbruggen AM, Nosco DL, Van Nerom CG, Bormans GM, Adriaens PJ, et al. Tc-99m-L,L-ethylenedicysteine: a renal imaging agent. I. Labelling and evaluation in animals. J Nucl Med 1992; 33:551-557.
10. Ratner S, Clarke HT. The action of formaldehyde upon cysteine. J Am Chem Soc 1937; 59:200-206.
11. Blondeau P, Berse C, Gravel D. Dimerization of an intermediate during the sodium in liquid ammonia reduction of I-thiazolidine-4-carboxylic acid. Can J Chem 1967; 45:49-52.
12. Van Nerom CG, Bormans GM, De Roo MJ, Verbruggen AM. First experience in healthy volunteers with Tc-99m-L,L-ethylenedicysteine, a new renal imaging agent. Eur J Nucl Med 1993; 20:738-746.
13. Surma MJ, Wiewiora J, Liniecki J. Usefulness of Tc-99m-N,N′- ethylene-1-dicysteine complex for dynamic kidney investigations. Nucl Med Commun 1994; 15:628-635.
14. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals. Cancer Biother Radiopharm 1998; 13:427-435.
15. 99mTc-ethylenedicysteine-colchicine for evaluation of antiangiogenic effects. Anticancer Drugs 1999; 10:685-692.
16. 99mTc-labeled metronidazole. Pharm Res 1999; 16:743-750.
17. 99mTc-EC-Annexin V. Cancer Biother Radiopharm 2001; 16:73-84.
18. 99mTc-EC-endostatin. Cancer Biother Radiopharm 2002; 17:233-246.
19. 99mTc- ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs 2003; 14:49-56.
20. 99mTc ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology 2003; 226:465-473.
21. 99mTc-labeled metronidazole. Stroke 2003; 34:982-986.
22. Chang HC, Weng CF. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol Rep 2001; 8:1321-1325.
23. Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 2003; 26:S103-S109.
24. Stabin M. MIRDOSE: the personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
25. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. J Natl Cancer Inst 2003; 95: 1440-1452.
26. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3:53-61.
27. Schwab JM, Schluesener HJ, Meyermann R, Serhan CN. COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics? Prostaglandins Leukot Essent Fatty Acids 2003; 69: 339-343.
28. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 2000; 31:S202-S210.
29. Schwab JM, Schluesener HJ, Laufer S. COX-3: just another COX or the solitary elusive target of paracetamol? Lancet 2003; 361:981-982.
30. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc Natl Acad Sci USA 2002; 99:13371-13373.